MARKET

MBRX

MBRX

Moleculin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9594
+0.0094
+0.99%
After Hours: 0.9100 -0.0494 -5.15% 17:57 01/17 EST
OPEN
0.9700
PREV CLOSE
0.9500
HIGH
0.9700
LOW
0.9360
VOLUME
180.13K
TURNOVER
--
52 WEEK HIGH
3.150
52 WEEK LOW
0.7772
MARKET CAP
43.87M
P/E (TTM)
-2.6628
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MBRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MBRX News

  • Moleculin Highlights New Data Showing Reversal Of Tumor Activity In Animal Models
  • Benzinga.12/19/2019 12:34
  • Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models
  • PR Newswire.12/19/2019 12:30
  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.12/06/2019 03:03
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters.12/05/2019 20:32

More

Industry

Pharmaceuticals
+0.13%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About MBRX

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.
More

Webull offers Moleculin Biotech Inc (MBRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.